Kopiju skaita izmaiņas HER2 pozitīvos krūts audzējos
No Thumbnail Available
Date
2020
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Rīgas Stradiņa universitāte
Rīga Stradiņš University
Rīga Stradiņš University
Abstract
Krūts vēzis ir visizplatītākais vēzis sievietēm ar mirstību gadā
likme 32,7 par 100,00 Latvijā1. Aptuveni 30% sieviešu ar ICD diagnozi liecina C-50
cilvēka epidermas augšanas faktora receptora (HER2) pārmērīga ekspresija, ko arī izmanto
kā prognostisks līdzeklis, jo tas ir saistīts ar paaugstinātu agresivitāti un zemāku slimības neskartu
laiks2. Parasti pārmērīgu ekspresiju identificē, izmantojot imūnhistoķīmiju (IHC), kas
nosaka HER2 olbaltumvielu ekspresijas līmenī. Tie identificētie pacienti tiek ārstēti ar tālāk
Trastuzumabs (Herceptin) papildus viņu ķīmijterapijai, lai panāktu šūnu cikla apturēšanu3, bet
ierobežojot šo iedarbību, šķiet, ka tikai 30% ārstēto pacientu reaģē pietiekami uz
ārstēšana.
Šis pētījums izceļ augstu viltus pozitīvo rādītāju līmeni (61% HER 2 + grupā) un
arī nepatiesi negatīvs (14% HER 2 grupā). Hromotripsis divreiz biežāk sastopams
patiesi HER 2 pozitīvi pacienti.
Breast cancer is the most common cancer in women, with an annual mortality rate of 32,7 per 100,00 in Latvia1. Around 30% of women with the ICD diagnosis C-50 show an overexpression for the human epidermal growth factor receptor (HER2) which is also used as a prognostic tool as it is associated with increased aggressiveness and lower disease-free time2. Commonly overexpression’s are identified using immunohistochemistry (IHC) which detects HER2 on a protein expression level. Those identified patients are further treated with Trastuzumab (Herceptin) in addition to their chemotherapy to achieve cell cycle arrest3 but limiting the effect to that only 30 % of treated patients seem to respond adequate to the treatment. This study outlines a high rate of false positive (61 % in HER 2 + group) and also false negative (14 % in HER 2 – group) rate. Chromothripsis is twice as likely to occur in true HER 2 positive patients.
Breast cancer is the most common cancer in women, with an annual mortality rate of 32,7 per 100,00 in Latvia1. Around 30% of women with the ICD diagnosis C-50 show an overexpression for the human epidermal growth factor receptor (HER2) which is also used as a prognostic tool as it is associated with increased aggressiveness and lower disease-free time2. Commonly overexpression’s are identified using immunohistochemistry (IHC) which detects HER2 on a protein expression level. Those identified patients are further treated with Trastuzumab (Herceptin) in addition to their chemotherapy to achieve cell cycle arrest3 but limiting the effect to that only 30 % of treated patients seem to respond adequate to the treatment. This study outlines a high rate of false positive (61 % in HER 2 + group) and also false negative (14 % in HER 2 – group) rate. Chromothripsis is twice as likely to occur in true HER 2 positive patients.
Description
Medicīna
Medicine
Veselības aprūpe
Health Care
Medicine
Veselības aprūpe
Health Care
Keywords
krūts vēzis, HER2, CNV, Trastuzumab, Breast Cancer, HER2, CNV, Trastuzumab